ATARA Biotherapeutics (ATRA) to Present Data from Ongoing CMV-CTL Phase 2 in CMV-Specific CTL
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced that Phase 2 results from its allogeneic T-cell product candidate, CMV-CTL, will be presented by its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) during the 58th American Society of Hematology (ASH) Annual Meeting. The meeting will take place in San Diego, California from December 3-6, 2016.
The presentation will highlight additional efficacy and safety data from the company’s ongoing Phase 2 trial of CMV-CTL in the treatment of patients with refractory CMV infections that occur following HCT and includes results in patients with viral mutations conferring resistance to available antiviral therapies. CMV-CTL is an investigational therapy in which a healthy donor’s T-cells are stimulated to recognize CMV antigens, or viral proteins, expressed in the cells of patients infected with CMV.
"We are encouraged by the efficacy and safety results being reported at ASH on the use of CMV-CTL in patients with CMV mutations conferring resistance to antiviral therapy and we look forward to our continued discussions with the FDA on late stage development to support potential approval of our CMV-CTL product candidate," said Chris Haqq M.D., Ph.D., Executive Vice President of Research and Development and Chief Scientific Officer of Atara Bio. "The management of CMV is clinically challenging and outcomes can be poor after currently available anti-viral therapies have been exhausted or when these therapies are rendered ineffective by resistance mutations in the virus."
Details of the presentation are as follows:
Title: Third Party CMV-Specific Cytotoxic T Cells for Treatment of Antiviral Resistant CMV Infection after Hematopoietic Stem Cell Transplant Publication Number: 61 Session Type: Oral Session Presenter: Susan Prockop, MD Session Name: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Post-Transplant Complications Session Date: Saturday, December 3, 2016 Session Time: 7:30 AM - 9:00 AM Presentation Time: 7:30 AM Room: Manchester Grand Hyatt San Diego, Grand Hall B
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PICO Holdings (PICO) Announces Leadership, Governance Changes; Terminates Central Square Agreement
- Porter Bancorp (PBIB) Shares Active Following Kentucky Court of Appeals Verdict
- Illinois Tool Works (ITW) Updates on Enterprise Strategy; Guides FY17 EPS Inline
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!